I-Y Choi1, S-P Lee, D R Denney, S G Lynch. 1. Hoglund Brain Imaging Center, Department of Neurology, University of Kansas Medical Center, Kansas City, KS 66160, USA. ichoi@kumc.edu
Abstract
BACKGROUND: Disability levels for patients with secondary progressive multiple sclerosis (SPMS) often worsen despite a stable MRI T(2) lesion burden. The presence of oxidative stress in the absence of measurable inflammation could help explain this phenomenon. In this study, the assessment of an in vivo marker of oxidative stress, cerebral glutathione (GSH), using magnetic resonance chemical shift imaging (CSI) is described, and GSH levels were compared in patients with SPMS and healthy controls. OBJECTIVE: To assess whether GSH, a key antioxidant in the brain, is lower in the SPMS patients compared to matched controls. METHODS: Seventeen patients with SPMS (Expanded Disability Status Scale=4.0-7.0; length of MS diagnosis=19.4 ± 7 years) and 17 age- and gender-matched healthy controls were studied. GSH levels were measured in the fronto-parietal regions of the brain using a specially designed magnetic resonance spectroscopy technique, CSI of GSH, at 3T. RESULTS: The levels of GSH were lower for SPMS patients than for controls, the largest reduction (18.5%) being in the frontal region (p=0.001). CONCLUSION: The lower GSH levels in these patients indicate the presence of oxidative stress in SPMS. This process could be at least partially responsible for ongoing functional decline in SPMS.
BACKGROUND: Disability levels for patients with secondary progressive multiple sclerosis (SPMS) often worsen despite a stable MRI T(2) lesion burden. The presence of oxidative stress in the absence of measurable inflammation could help explain this phenomenon. In this study, the assessment of an in vivo marker of oxidative stress, cerebral glutathione (GSH), using magnetic resonance chemical shift imaging (CSI) is described, and GSH levels were compared in patients with SPMS and healthy controls. OBJECTIVE: To assess whether GSH, a key antioxidant in the brain, is lower in the SPMS patients compared to matched controls. METHODS: Seventeen patients with SPMS (Expanded Disability Status Scale=4.0-7.0; length of MS diagnosis=19.4 ± 7 years) and 17 age- and gender-matched healthy controls were studied. GSH levels were measured in the fronto-parietal regions of the brain using a specially designed magnetic resonance spectroscopy technique, CSI of GSH, at 3T. RESULTS: The levels of GSH were lower for SPMS patients than for controls, the largest reduction (18.5%) being in the frontal region (p=0.001). CONCLUSION: The lower GSH levels in these patients indicate the presence of oxidative stress in SPMS. This process could be at least partially responsible for ongoing functional decline in SPMS.
Authors: Rohit Bakshi; Alan J Thompson; Maria A Rocca; Daniel Pelletier; Vincent Dousset; Frederik Barkhof; Matilde Inglese; Charles R G Guttmann; Mark A Horsfield; Massimo Filippi Journal: Lancet Neurol Date: 2008-07 Impact factor: 44.182
Authors: Fahmy Aboul-Enein; Martin Krssák; Romana Höftberger; Daniela Prayer; Wolfgang Kristoferitsch Journal: PLoS One Date: 2010-07-20 Impact factor: 3.240
Authors: Radhika Srinivasan; Helene Ratiney; Kathyrn E Hammond-Rosenbluth; Daniel Pelletier; Sarah J Nelson Journal: Magn Reson Imaging Date: 2009-08-19 Impact factor: 2.546
Authors: In-Young Choi; Phil Lee; Peter Adany; Abbey J Hughes; Scott Belliston; Douglas R Denney; Sharon G Lynch Journal: Mult Scler Date: 2017-06-01 Impact factor: 6.312
Authors: Janna L Harris; Hung-Wen Yeh; Russell H Swerdlow; In-Young Choi; Phil Lee; William M Brooks Journal: Neurobiol Aging Date: 2014-01-23 Impact factor: 4.673
Authors: In-Young Choi; Phil Lee; Douglas R Denney; Kendra Spaeth; Olivia Nast; Lauren Ptomey; Alexandra K Roth; Jo Ann Lierman; Debra K Sullivan Journal: Am J Clin Nutr Date: 2014-12-10 Impact factor: 7.045
Authors: Mark J Hackett; Shari E Smith; Phyllis G Paterson; Helen Nichol; Ingrid J Pickering; Graham N George Journal: ACS Chem Neurosci Date: 2012-01-02 Impact factor: 4.418